Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
RegulatoryapprovedFayuviPositive
AI Analysis
Summary
Ultragenyx received FDA approval for Fayuvi to treat Sanfilippo syndrome, a rare childhood neurodegenerative disease. The approval, alongside an expected August nod for another gene therapy, helps offset recent asset failures including an Angelman syndrome program.
Outcome Details
FDA approval of Fayuvi for Sanfilippo syndrome
Importance:8/10
Sentiment:
0.70
FDA approvalgene therapyrare diseaseSanfilippo syndromeUltragenyxFayuvi
Related Companies
Read the original article
Published by BioSpace on September 28, 2026 4:02 AM